Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTU-135 in Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
2007-000171-41Phase 3
- Sponsor
- Altus Pharmaceuticals Inc.
- Start
- Jul 2007
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exocrine pancreatic insufficiency (EPI) and Exocrine pancreatic insufficiency due to cystic fibrosis comparing ALTU-135 with Placebo (2 arms). Primary endpoint: Mean change in coefficient of fat absorption (CFA).
02
Drugs
liprotamase
03
Conditions
exocrine pancreatic insufficiency (EPI)Exocrine pancreatic insufficiency due to cystic fibrosis
Beyond the preview
Go deeper on 2007-000171-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000171-41.